Skip to main content
Skip table of contents

Submission of Monolix analysis to regulatory agencies

Monolix is used for regulatory submissions (including the FDA and the EMA) of population PK and PK/PD analyses. Monolix analyses for first in human dose estimation, dose-finding studies and registration studies have been routinely and successfully submitted to the FDA, EMA and other agencies. The FDA and the EMA do have access to Monolix and the modelling experts to understand, review and run Monolix. In addition, regulators are also taking part in publishing research articles with Monolix.

Files to include for submissions

Regulatory guidelines provide only little information on the required electronic files for submission. Based on exchanges with regulatory agencies and confirmed through past regulatory submissions using Monolix, the following listed files in Table 1 and 2 are required for a Monolix analysis submission package.

Table 1 lists all files needed to run Monolix and reproduce the results and diagnostic plots. Attention must be paid to use relative file path definitions (Settings > Preferences > Use relative path) to facilitate the project transfer from one computer system to another. It is also possible to create a .zip containing all requires input files, as well as all results with Export > Share project. Table 2 lists the files containing the run results.

A Monolix run will automatically produce a large number of additional files. However, the files listed in Table 1 and Table 2 are sufficient to entirely reproduce the results and share the main findings. Note that all files are in a human readable format. Thus, the information contained in these files can also be included into the appendices of the report creating one single document that contains everything to reproduce the results.

All MonolixSuite file types are accepted by the FDA and are listed in the "Specifications for File Format Types Using eCTD Specifications".

Table 1 Monolix files required for reproducibility of results

File

When to include

Content

File extension

Dataset file

Always

Input dataset

.txt, .csv, .xls, .xlsx, .sas2bdat or .xpt

Additional columns file

If “additional columns” in data formatting module was used

Additional columns appended to the dataset

.txt, .csv, .xls, .xlsx, .sas2bdat or .xpt

Monolix project file (.mlxtran)

Always

Path to dataset, dataset settings (column tagging, filters, etc), path to structural model, statistical model, algorithm settings, estimation tasks

.mlxtran

Structural model file

If not using a model from the libraries

Structural model in mlxtran syntax

.txt

Plot properties
(.mlxproperties)

Always (except if file not present because only default settings)

Plot stratify, settings and preferences

.mlxproperties

Model building configuration file

If model building (covariate search) has been run via the command line

Covariate search method, settings and relationships to test

.txt

Conv. assessment configuration file

If convergence assessment has been run via the command line

Convergence assessment settings and estimation tasks ro tun

.txt

Bootstrap configuration file

If bootstrap has been run via the command line

Bootstrap settings

.txt

Table 2 Monolix files containing the key results

File

When to include

Content

File extension

summary.txt

Always

Results of population parameter, EBEs, conditional distribution, standard errors and likelihood tasks.
Number of iterations and dataset recap (number of individuals, observations and doses).

.txt

populationParameters.txt

Always

Population parameters and standard errors
with 15 digits

.txt

ModelBuilding/
modelBuilding.txt

If model building (covariate search) has been run

Overview of all tested models, their likelihood and BICc

.txt

Bootstrap/
populationSummary.txt

If bootstrap has been run

Summary statistics of bootstrap estimates

.txt

Assessment/
assessment.txt

If convergence assessment has been run

Parameter estimate of each assessment run

.txt

Examples of submissions

This section lists examples of Clinical pharmacology reviews (FDA) and Assessment reports (EMA) explicitly mentioning the use of Monolix.

Submissions to the FDA using Monolix

  • ZALTRAP (Aflibercept) - Sanofi - Clinical pharmacology review (link)

  • CORLANOR (Ivabradine) - Amgen - Clinical pharmacology review (link)

  • JEVTANA (Cabazitaxel) - Sanofi - Clinical pharmacology review (link)

  • PONVORY (Ponesimod) - Janssen - Clinical pharmacology review (link)

  • RYZNEUTA (Efbemalenograstim) - Evive Biotechnology Singapore - Integrated review (link)

  • EXBLIFEP (Cefepime and enmetazobactam) - Allecra Therapeutics - Integrated review (link)

Submission to the EMA using Monolix

  • OSELTAMIVIR (Tamiflu) - Roche - Assesment report (link)
    (Procedure No. EMEA/H/C/000402/II/0110/G – EMA/CHMP/186699/2015)

  • BOSENTAN (Tracleer) - Actelion - Assessment report (link)
    (Procedure No. EMEA/H/C/000401/II/0066 – EMA/168487/2015)

  • ISATUXIMAB (Sarclisa) - Sanofi - Assesment report (link) and Statistical analysis plan (link)
    (Procedure No. EMEA/H/C/004977/II/0003 – EMA/CHMP/186236/2021)

Publications by the FDA using MonolixSuite

This section lists a few (non-exhaustive) publications by the FDA using MonolixSuite.

  • “Plasma pharmacokinetics of ceftiofur metabolite desfuroylceftiofur cysteine disulfide in holstein steers: application of nonlinear mixed-effects modeling.”, J Vet Pharmacol Ther 2016 Apr;39(2):149-56, DOI: 10.1111/jvp.12245. O. A. Chiesa, S. Feng, P. Kijak,E. A. Smith, H. Li and J. Qiu.

  • “Quantification of disease progression and dropout for Alzheimer’s disease.”, Int. Journal of Clinical Pharmacology and Therapeutics, Volume 51 – February (120 – 131),(Doi: 10.5414/CP201787). D. William-Faltaos, Y. Chen, Y. Wang, J. Gobburu,, and H. Zhu.

  • “Estimation of Population Pharmacokinetic Parameters Using MLXTRAN Interpreter in MONOLIX 2.4”, D. William Faltaos, Acop 2009.

Regulatory guidelines

JavaScript errors detected

Please note, these errors can depend on your browser setup.

If this problem persists, please contact our support.